全球首款：第一三共B7H3 ADC启动III期临床 - 网易
2024年1月13日 · 1月12日，clinicaltrials.gov网站显示，第一三共启动了DS-7300（ifinatamab deruxtecan，I-DXd）的III期临床试验（IDeate-2）。 该药物是首款进入III期阶段的B7H3 ADC …
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody …
2022年4月1日 · Here, we report the development of DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a potent DNA topoisomerase I inhibitor, and its in vitro profile, …
DS-7300 is an antibody-drug conjugate (ADC) composed of a humanized anti–B7- H3 immunoglobulin G1 (IgG1) monoclonal antibody conjugated to a drug linker that releases its …
第一三共B7H3 ADC药物DS-7300a启动国内III期临床，针对小细胞 …
2024年7月30日 · DS-7300a 由人源化抗 B7-H3 mAb 、酶促裂解的四肽接头和有效的 TOP1 抑制剂组成， DXd 。 DS-7300a 旨在与细胞表面的 B7-H3 结合；结合后，它被内化到癌细胞中， …
新型ADC药物I-DXd（DS-7300a）治疗复发性广泛期小细胞肺癌， …
Ifinatamab deruxtecan （I-DXd，DS-7300a）是一种新型的抗体药物偶联物（ADC），由第一三共公司开发。 它由三部分组成：人源化抗 B7-H3 IgG1单克隆抗体、通过可裂解四肽连接子与拓 …
晚期小细胞肺癌治疗新药DS-7300 - 知乎 - 知乎专栏
本文主要介绍笔者看来最有希望的治疗药物， ds-7300 ，也称为 i-dxd 。 这是一个adc类的药物，抗体部分的靶点是 b7-h3 ，毒素部分用的是和 ds-8201 相同的dxd。 作为都是第一三共的研 …
DS-7300 Continues to Show Promising Durable Response in …
2022年9月10日 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-7300 is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a number of …
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated …
This global phase 2 trial is evaluating the efficacy and safety of two doses (8 mg/kg or 12 mg/kg) of DS-7300 in patients with histologically or cytologically confirmed extensive-stage SCLC that …
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based …
We generated DS-7300a, a novel B7-H3–targeting ADC, using DXd-ADC technology, which is composed of a humanized anti–B7-H3 mAb, an enzymatically cleavable tetra-peptide–based …
About DS-7300 DS-7300 is an investigational B7-H3 directed ADC and is one of six ADCs currently in clinical development in the oncology pipeline of Daiichi Sankyo. Designed using …